Galectin Therapeutics
7 Wells Avenue
Suite #34
Newton
Massachusetts
02459
United States
Tel: 617-559-0033
Fax: 617-928-3450
Website: http://www.galectintherapeutics.com/
236 articles about Galectin Therapeutics
-
Galectin Therapeutics to Webcast Corporate Update at Annual Meeting of Shareholders
12/11/2017
The webcast is expected to commence at approximately 9 a.m. ET on Thursday, December 14, 2017.
-
Galectin Therapeutics to Present Results From Phase IIb NASH-CX Trial on December 5, 2017
12/5/2017
The company will host a conference call and webcast, including a slide presentation, beginning at 8:30 a.m. ET on December 5, 2017.
-
There was a positive trend in the total group of patients but the difference did not reach statistical significance for this primary endpoint.
-
Galectin: Combination Immunotherapy of Pembrolizumab With the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma From a Phase Ib Clinical Trial
11/13/2017
The objective response rate in advanced melanoma was 62.5% (five of eight subjects).
-
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017
11/13/2017
The Summit, which is dedicated to the translation of fibrotic mechanisms into clinically effective therapeutics, will take place November 13-14 at the Hyatt Regency Boston, Boston, MA.
-
Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update December 2019
11/7/2017
These results are included in the Company’s Quarterly Report on Form 10-Q, which has been filed with the U.S. SEC and is available at www.sec.gov.
-
Galectin Therapeutics to Present Clinical Data at The Liver Meeting 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis
10/20/2017
Research to be presented demonstrates VCTE liver stiffness measurement is a surrogate for identifying portal hypertension in patients with compensated NASH cirrhosis.
-
Galectin Receives Notice Of Chinese Allowance To Grant A Key Patent For Composition Of Matter For GR-MD-02
9/12/2017
-
Clarification: Galectin Reports 2017 Second Quarter Financial Results And Provides Business Update
8/18/2017
-
Galectin Reports 2017 Second Quarter Financial Results And Provides Business Update
8/14/2017
-
Patent For Enhancing Immunotherapy In Cancer Treatment Granted To Galectin
7/25/2017
-
Patent For Reducing Inflammatory Response Granted To Galectin
6/21/2017
-
Galectin Announces Important Milestones Towards Completion Of NASH CX Trial
6/13/2017
-
Autoimmune Disease Patent Granted To Galectin
6/6/2017
-
Galectin Reports 2017 First Quarter Financial Results And Provides Business Update
5/15/2017
-
Galectin Launches The Liver Line, An Online Community And Publication On Liver Health And Liver Disease
5/3/2017
-
Galectin Receives Notice Of Japanese Decision To Grant A Composition Of Matter Patent For GR-MD-02
4/25/2017
-
Galectin’s GR-MD-02 Demonstrates Efficacy In Patients With Moderate To Severe Plaque Psoriasis
3/6/2017
-
Galectin Stock Craters After Phase IIa NASH Failure
9/28/2016
-
Galectin Reports Second Quarter 2016 Financial Results And Provides Business Update
8/9/2016